Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV) and Gilead Sciences (GILD)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV – Research Report) and Gilead Sciences (GILD – Research Report).
Confident Investing Starts Here:
AbbVie (ABBV)
In a report issued on May 31, Courtney Breen from Bernstein maintained a Hold rating on AbbVie. The company's shares closed last Friday at $186.11.
According to TipRanks.com, Breen is a 2-star analyst with an average return of -0.1% and a 27.8% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Merck & Company, and Gilead Sciences.
AbbVie has an analyst consensus of Moderate Buy, with a price target consensus of $212.13, implying a 14.7% upside from current levels. In a report issued on May 30, Berenberg Bank also maintained a Hold rating on the stock with a $170.00 price target.
Gilead Sciences (GILD)
In a report released yesterday, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences, with a price target of $125.00. The company's shares closed last Friday at $110.08.
According to TipRanks.com, Biegler is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -14.6% and a 28.7% success rate. Biegler covers the Healthcare sector, focusing on stocks such as Acrivon Therapeutics, Inc., Day One Biopharmaceuticals, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Gilead Sciences is a Strong Buy with an average price target of $120.47, implying a 7.9% upside from current levels. In a report issued on May 21, Jefferies also maintained a Buy rating on the stock with a $130.00 price target.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
High Growth Tech Stocks To Watch In The US June 2025
Over the last 7 days, the United States market has risen by 2.0% and is up 12% over the past year, with earnings forecasted to grow by 14% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and robust financial health to capitalize on these favorable conditions. Name Revenue Growth Earnings Growth Growth Rating Super Micro Computer 26.38% 39.09% ★★★★★★ Mereo BioPharma Group 53.63% 66.57% ★★★★★★ Ardelyx 20.78% 59.46% ★★★★★★ Travere Therapeutics 26.41% 64.47% ★★★★★★ TG Therapeutics 26.46% 38.75% ★★★★★★ Alnylam Pharmaceuticals 23.64% 61.12% ★★★★★★ AVITA Medical 27.28% 60.66% ★★★★★★ Alkami Technology 20.54% 76.67% ★★★★★★ Ascendis Pharma 35.15% 60.20% ★★★★★★ Lumentum Holdings 21.59% 110.32% ★★★★★★ Click here to see the full list of 230 stocks from our US High Growth Tech and AI Stocks screener. We're going to check out a few of the best picks from our screener tool. Simply Wall St Growth Rating: ★★★★☆☆ Overview: AbbVie Inc. is a research-based biopharmaceutical company focused on the development, manufacture, and sale of medicines and therapies globally, with a market capitalization of approximately $328.75 billion. Operations: AbbVie generates revenue primarily from its Innovative Medicines and Therapies segment, which accounts for $57.37 billion. The company is involved in the research, development, manufacture, and sale of biopharmaceutical products worldwide. AbbVie's strategic alliance with the Sarah Cannon Research Institute, announced on May 28, 2025, underscores its commitment to accelerating cancer therapy innovations. This collaboration is expected to enhance clinical trial delivery and drug development efficiency through SCRI's advanced research capabilities. Concurrently, AbbVie's recent FDA approval of EMRELIS™ for specific lung cancer patients highlights its ongoing focus on addressing critical medical needs through targeted therapies. These developments reflect AbbVie's robust investment in R&D which is integral to advancing its pipeline and maintaining competitive advantage in biotech innovation. Get an in-depth perspective on AbbVie's performance by reading our health report here. Explore historical data to track AbbVie's performance over time in our Past section. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Fair Isaac Corporation is a company that specializes in developing software with analytics and digital decisioning technologies for global markets, with a market cap of $42.02 billion. Operations: Fair Isaac Corporation generates revenue primarily through its Scores segment, contributing $1.02 billion, and Software segment, which adds $817 million. Fair Isaac Corporation (FICO) is demonstrating robust growth in the tech sector, particularly through its innovative AI solutions that enhance client operations. Recently, FICO has been pivotal for Vitality's Care Hub, revolutionizing healthcare management by integrating digital pathways that reduce operational costs and improve claims processing efficiency. This collaboration underscores FICO's commitment to leveraging technology for transformative business solutions. Financially, FICO is on a strong trajectory with a 13.1% annual revenue growth and an 18% earnings growth forecast, outpacing the US market averages of 8.6% and 14.4%, respectively. Additionally, their strategic use of R&D investment enhances their competitive edge in the high-stakes tech landscape. Dive into the specifics of Fair Isaac here with our thorough health report. Gain insights into Fair Isaac's past trends and performance with our Past report. Simply Wall St Growth Rating: ★★★★☆☆ Overview: Oracle Corporation provides a range of products and services for enterprise IT environments globally, with a market capitalization of approximately $464.18 billion. Operations: Oracle generates revenue primarily from three segments: Cloud and License ($47.60 billion), Services ($5.26 billion), and Hardware ($2.93 billion). The company's business model focuses on providing comprehensive IT solutions, with a significant portion of its income derived from cloud services and software licensing. Oracle's strategic initiatives in AI and cloud solutions are reshaping its market presence, particularly through its recent partnerships and client engagements. The company's involvement in the Stargate UAE project alongside global tech leaders underscores its commitment to pioneering next-generation AI infrastructures, which is poised to enhance capabilities across various sectors including healthcare and finance. This collaboration not only expands Oracle's technological footprint but also aligns with broader economic development goals by fostering innovation. Moreover, Oracle's R&D investments remain robust, as evidenced by a consistent allocation of resources towards developing cutting-edge technologies. For instance, the company has strategically increased its R&D expenditure to $6.5 billion in 2024 from $6.1 billion the previous year, reflecting a growth of approximately 6.56%. This investment fuels advancements in Oracle's cloud services and software solutions, ensuring that it stays at the forefront of technological innovation and continues to offer competitive services to its clients like Lyntia Networks, enhancing their operational efficiencies through advanced OSS solutions powered by Oracle Communications Cloud Native Suite. Unlock comprehensive insights into our analysis of Oracle stock in this health report. Learn about Oracle's historical performance. Unlock our comprehensive list of 230 US High Growth Tech and AI Stocks by clicking here. Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports. Take control of your financial future using Simply Wall St, offering free, in-depth knowledge of international markets to every investor. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NYSE:ABBV NYSE:FICO and NYSE:ORCL. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
As more companies pivot into crypto, who's buying bitcoin?
Public companies — especially Strategy (MSTR) — now hold over 3% of the bitcoin (BTC-USD) in circulation, according to Bernstein data. Yahoo Finance senior reporter David Hollerith sits down with the Market Domination Overtime team to speak more on the latest crypto-buying trends from major companies. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here. Public companies are increasing their Bitcoin exposure and now hold more than 3% of all bitcoins in circulation. That's according to analysis from Bernstein Research. They say imitation is this is flattering, and if this trend comes on the heels of the business software company strategies, crypto buying, of course. To explain more about who's buying crypto and why, senior reporter David Hollerth is joining us. That's everybody's trying to follow the Michael Saler playbook now. Yeah, exactly. I mean, uh, why wouldn't you seeing the rise in Bitcoin at this point and you know it's an interesting, uh, dynamic. There's a premium premium between Bitcoins or excuse me, uh, strategies, uh. Market cap and the amount of bitcoins it holds and other companies that have done this even this year have also seen that but not all of them have so in some sense the investors that are putting money into this or the companies themselves are kind of uh it's seemingly magically creating money so that's obviously an interesting dynamic from just an overall market's perspective and you know we're paying a lot of attention to the companies and we've seen a little bit of investors. Limits to this trend last week GameStop and uh the president's namesake uh media company both uh reported doing these kind of strategies and uh or at least plans to, and their stocks dropped on the day so it's kind of an interesting trend to pay attention to, right? And we've seen strategies sometimes on individual days drop when it says it's sort of raising capital if investors view that as dilute of whatever they're doing, but you mentioned that. Premium, which is the thing that I guess other companies that are doing this are chasing, right? They want to get that to trade even better than Bitcoin has. What have you gotten in terms of explanations of why strategy trades at that premium to Bitcoin? Yeah, that's a good question. Um, I think it has to do with the fact that they take on a fair amount of leverage by issuing debt and then on top of that it's some sort of forward indication about the price of Bitcoin. And how well, uh, strategy and Michael Saylor are going to continue to accumulate it in the future that's the best explanation I have but if you look at a financial or an economics textbook, you're not gonna get a clear answer like that. So no, well, nor are you for Bitcoin in general, I suppose.
Yahoo
9 hours ago
- Yahoo
As more companies pivot into crypto, who's buying bitcoin?
Public companies — especially Strategy (MSTR) — now hold over 3% of the bitcoin (BTC-USD) in circulation, according to Bernstein data. Yahoo Finance senior reporter David Hollerith sits down with the Market Domination Overtime team to speak more on the latest crypto-buying trends from major companies. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime here.
